175 related articles for article (PubMed ID: 11723223)
1. Activity of 2-substituted lysophosphatidic acid (LPA) analogs at LPA receptors: discovery of a LPA1/LPA3 receptor antagonist.
Heise CE; Santos WL; Schreihofer AM; Heasley BH; Mukhin YV; Macdonald TL; Lynch KR
Mol Pharmacol; 2001 Dec; 60(6):1173-80. PubMed ID: 11723223
[TBL] [Abstract][Full Text] [Related]
2. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
3. Stereochemical properties of lysophosphatidic acid receptor activation and metabolism.
Yokoyama K; Baker DL; Virag T; Liliom K; Byun HS; Tigyi G; Bittman R
Biochim Biophys Acta; 2002 May; 1582(1-3):295-308. PubMed ID: 12069841
[TBL] [Abstract][Full Text] [Related]
4. Differential targeting of lysophosphatidic acid LPA
Olianas MC; Dedoni S; Onali P
Eur J Pharmacol; 2023 Nov; 959():176064. PubMed ID: 37758013
[TBL] [Abstract][Full Text] [Related]
5. Identification of a phosphothionate analogue of lysophosphatidic acid (LPA) as a selective agonist of the LPA3 receptor.
Hasegawa Y; Erickson JR; Goddard GJ; Yu S; Liu S; Cheng KW; Eder A; Bandoh K; Aoki J; Jarosz R; Schrier AD; Lynch KR; Mills GB; Fang X
J Biol Chem; 2003 Apr; 278(14):11962-9. PubMed ID: 12554733
[TBL] [Abstract][Full Text] [Related]
6. Initial structure-activity relationships of lysophosphatidic acid receptor antagonists: discovery of a high-affinity LPA1/LPA3 receptor antagonist.
Heasley BH; Jarosz R; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2004 Jun; 14(11):2735-40. PubMed ID: 15125924
[TBL] [Abstract][Full Text] [Related]
7. Molecular basis for lysophosphatidic acid receptor antagonist selectivity.
Sardar VM; Bautista DL; Fischer DJ; Yokoyama K; Nusser N; Virag T; Wang DA; Baker DL; Tigyi G; Parrill AL
Biochim Biophys Acta; 2002 May; 1582(1-3):309-17. PubMed ID: 12069842
[TBL] [Abstract][Full Text] [Related]
8. Selective blockade of lysophosphatidic acid LPA3 receptors reduces murine renal ischemia-reperfusion injury.
Okusa MD; Ye H; Huang L; Sigismund L; Macdonald T; Lynch KR
Am J Physiol Renal Physiol; 2003 Sep; 285(3):F565-74. PubMed ID: 12770838
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic Acid Receptor Agonism: Discovery of Potent Nonlipid Benzofuran Ethanolamine Structures.
Guillot E; Le Bail JC; Paul P; Fourgous V; Briand P; Partiseti M; Cornet B; Janiak P; Philippo C
J Pharmacol Exp Ther; 2020 Aug; 374(2):283-294. PubMed ID: 32409422
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of lysophosphatidic acid analogs.
Lynch KR; Macdonald TL
Biochim Biophys Acta; 2002 May; 1582(1-3):289-94. PubMed ID: 12069840
[TBL] [Abstract][Full Text] [Related]
11. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques.
Rother E; Brandl R; Baker DL; Goyal P; Gebhard H; Tigyi G; Siess W
Circulation; 2003 Aug; 108(6):741-7. PubMed ID: 12885756
[TBL] [Abstract][Full Text] [Related]
12. Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists.
Qian L; Xu Y; Simper T; Jiang G; Aoki J; Umezu-Goto M; Arai H; Yu S; Mills GB; Tsukahara R; Makarova N; Fujiwara Y; Tigyi G; Prestwich GD
ChemMedChem; 2006 Mar; 1(3):376-83. PubMed ID: 16892372
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of phosphonic and thiophosphoric acid derivatives of lysophosphatidic acid.
Santos WL; Heasley BH; Jarosz R; Carter KM; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2004 Jul; 14(13):3473-6. PubMed ID: 15177455
[TBL] [Abstract][Full Text] [Related]
14. Lysophosphatidic acid acts on LPA
Chabowski DS; Kadlec AO; Ait-Aissa K; Hockenberry JC; Pearson PJ; Beyer AM; Gutterman DD
Br J Pharmacol; 2018 Nov; 175(22):4266-4280. PubMed ID: 30153326
[TBL] [Abstract][Full Text] [Related]
15. Specific LPA receptor subtype mediation of LPA-induced hypertrophy of cardiac myocytes and involvement of Akt and NFkappaB signal pathways.
Chen J; Chen Y; Zhu W; Han Y; Han B; Xu R; Deng L; Cai Y; Cong X; Yang Y; Hu S; Chen X
J Cell Biochem; 2008 Apr; 103(6):1718-31. PubMed ID: 17891781
[TBL] [Abstract][Full Text] [Related]
16. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells.
Shida D; Kitayama J; Yamaguchi H; Hama K; Aoki J; Arai H; Yamashita H; Mori K; Sako A; Konishi T; Watanabe T; Sakai T; Suzuki R; Ohta H; Takuwa Y; Nagawa H
Exp Cell Res; 2004 Dec; 301(2):168-78. PubMed ID: 15530853
[TBL] [Abstract][Full Text] [Related]
17. Lysophosphatidic acid signaling via LPA
Fukushima K; Takahashi K; Yamasaki E; Onishi Y; Fukushima N; Honoki K; Tsujiuchi T
Exp Cell Res; 2017 Mar; 352(1):139-145. PubMed ID: 28189636
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylation and Internalization of Lysophosphatidic Acid Receptors LPA1, LPA2, and LPA3.
Alcántara-Hernández R; Hernández-Méndez A; Campos-Martínez GA; Meizoso-Huesca A; García-Sáinz JA
PLoS One; 2015; 10(10):e0140583. PubMed ID: 26473723
[TBL] [Abstract][Full Text] [Related]
19. Analysis of Edg-Like LPA Receptor-Ligand Interactions.
Balogh B; Pazmany T; Matyus P
Curr Pharm Des; 2015; 21(24):3533-47. PubMed ID: 25686617
[TBL] [Abstract][Full Text] [Related]
20. Lysophosphatidic acid regulates inflammation-related genes in human endothelial cells through LPA1 and LPA3.
Lin CI; Chen CN; Lin PW; Chang KJ; Hsieh FJ; Lee H
Biochem Biophys Res Commun; 2007 Nov; 363(4):1001-8. PubMed ID: 17923111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
